Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biocon Limited ( (IN:BIOCON) ) just unveiled an update.
Biocon Limited announced that its subsidiary, Biocon Pharma Limited, has received approval from the US FDA for its ANDA for Everolimus Tablets, which are used in organ transplantation. This approval enhances Biocon’s portfolio of complex drug products, potentially strengthening its market position and offering new opportunities for growth.
More about Biocon Limited
Biocon Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of complex drug products. The company is known for its vertically integrated approach and serves markets with a focus on prescription medications.
YTD Price Performance: -17.25%
Average Trading Volume: 164,169
Current Market Cap: 366.4B INR
See more data about BIOCON stock on TipRanks’ Stock Analysis page.